Clinical Trials

As part of the National Institute of Health’s Clinical Islet Transplantation Consortium, the Schulze Diabetes Institute is one of 5 facilities in the United States currently conducting clinical trials to identify the most effective combination of anti-rejection medications and strategies to best protect the newly transplanted islets.

This is the final stage before allo-islet transplantation may become widely available outside the clinical trial arena.

Clinical trials enrolling subjects

Trial: CIT-06

The purpose of this trial is to study allo-islet transplantation in patients with Type 1 diabetes who have previously had a kidney transplant.

Click here to see if you're eligible for this trial.

Clinical trials no longer enrolling subjects

The following trials have met enrollment goals and are no longer enrolling. Patients who have received islet transplants continue to be followed under these studies.

Trial: CIT-07

The goal of this trial is to study state-of-the-art modalities in immunosuppression and strategies to improve long-term islet graft survival.

Trial: CIT-03

Using similar strategies as CIT-07, the goal is to study the ability of a specific immunosuppressive agent, deoxyspergualin, to improve long-term islet graft survival.

Future clinical trials

The University of Minnesota Schulze Diabetes Institute has an active research program and new clinical trials may be available in the future.  If you are interested in participating in a future clinical trail, please click here. We will keep your information until a future trial becomes available.